Search

Your search keyword '"Giuseppe Viscardi"' showing total 73 results

Search Constraints

Start Over You searched for: Author "Giuseppe Viscardi" Remove constraint Author: "Giuseppe Viscardi"
73 results on '"Giuseppe Viscardi"'

Search Results

1. Analysis of phase III clinical trials in metastatic NSCLC to assess the correlation between QoL results and survival outcomes

2. Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemoimmunotherapy: preclinical data and a retrospective study in Southern Italy

3. PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1

4. Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial

5. Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients

6. Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC

7. Circulating biomarkers in malignant pleural mesothelioma

8. Asymptomatic azygos vein overflow in a young patient with primary mediastinal seminoma

9. Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC

10. Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy

11. Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer

12. Role and targeting of anaplastic lymphoma kinase in cancer

14. Moving Immune Checkpoint Inhibitors to Early Non-Small Cell Lung Cancer: A Narrative Review

15. Health-related quality of life is underestimated and underreported in phase III clinical trials in NSCLC

16. TERAVOLT: Thoracic Cancers International COVID-19 Collaboration

17. Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation

18. Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology

19. A Trimodality, Four-Step Treatment including Chemotherapy, Pleurectomy/Decortication and Radiotherapy in Early-Stage Malignant Pleural Mesothelioma: A Single-Institution Retrospective Case Series Study

20. Asymptomatic azygos vein overflow in a young patient with primary mediastinal seminoma

21. Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy

22. Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program

23. A systematic review and meta-analysis of early death (ED) upon immune checkpoint inhibitors (ICI) alone or combined with other non-ICIs treatments as first-line treatment of advanced solid tumors

24. Chemotherapy-induced bowel ischemia: diagnostic imaging overview

25. Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers

26. Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system

27. How i treat malignant pleural mesothelioma

28. 1388P Poziotinib in advanced NSCLC with EGFR or HER2 exon 20 insertion mutation: Initial results from a single site expanded access program

29. Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: Young oncologists' perspective

30. Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota

31. P40.08 Bone-Targeted Agents Improve Survival in High Bone Tumor Burden Advanced Non-Small-Cell-Lung Cancer Patients Treated With PD-(L)1 Inhibitors

32. 1830P Early deaths (ED) upon first-line immunecheckpoint inhibitors (ICI) alone or combined to other non-ICI drugs across solid cancers: A systematic review and meta-analysis

33. 1327P Impact of bone targeted agents (BTA) in advanced non-small cell lung cancer (aNSCLC) patients (pts) with high bone tumor burden (HBTB) treated with PD(L)1 inhibitors (ICIs)

34. P-198 Prevalence of deleterious DPYD variants in patients with gastrointestinal malignancies: Real-world data from a single institution in Italy

35. Abstract S12-03: Thoracic cancers international COVID-19 collaboration (TERAVOLT): Small-cell lung cancer and other rare thoracic malignancies

36. 1329P Immune checkpoint inhibitors in advanced NSCLC patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers in a real world experience

37. 1335P Anti-tumour efficacy of cetuximab plus avelumab in NSCLC through induction of ADCC: Final data from CAVE-lung trial

38. Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: case report and translational study

39. Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC

40. Epsilon: A prognostic score for immunotherapy in advanced non-small-cell lung cancer: A validation cohort

41. 184P Bone-targeted agents (BTA) improve survival in advanced non-small cell lung cancer (aNSCLC) patients (pts) with high bone tumor burden (HBTB) treated with PD-(L)-1 inhibitors (ICIs)

42. 196P A pivotal multicenter translational research project on malignant pleural mesothelioma (MPM): Preliminary results

43. P33.01 Circulating Extracellular Vesicles as Biomarkers for Immune-Checkpoint Inhibitors in Advanced NSCLC

44. 15P A pivotal multicenter translational research project on malignant pleural mesothelioma (MPM): Preliminary results

45. 1278P Hyperprogressive disease (HPD) upon first-line PD-1/PD-L1 inhibitors (ICI) as single agent or in combination with platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients (pts)

46. Abstract 4480: Circulating and tumor associated neutrophil subtypes correlate with hyperprogressive disease (HPD) upon immunecheckpoint inhibitors (ICI) in advanced non-small cell lung cancer (aNSCLC) patients (pts) and in vivo models

47. Efficacy and safety of immunotherapy in non-small cell lung cancer patients with poor performance status

48. Circulating and tumor-associated neutrophil subtypes discriminate hyperprogressive disease (HPD) from conventional progression (PD) upon immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients (pts) and in vivo models

49. Facing the First-line in Metastatic Non-small-cell Lung Cancer – Immunotherapy and Chemotherapy

50. Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer

Catalog

Books, media, physical & digital resources